Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tamarindo1on Aug 26, 2021 10:24am
148 Views
Post# 33766886

RE:RE:RE:RE:RE:RE:RE:RE:The delayed newsletter

RE:RE:RE:RE:RE:RE:RE:RE:The delayed newsletter
Drug Companies Sell Us Remedies for Problems Caused by Their Own Products—And the Federal Government Helps Them
This should be a clear violation of antitrust laws.
By Kate Harveston / AlterNet January 30, 2018, 11:07 AM GMT
3318
Print

Like most folks, you dutifully rub shampoo into your hair daily or a few times each week. After it

strips out your hair’s natural moisture and liveliness, you apply a conditioner to get that moisture

and liveliness back.

much about modern life seems to follow this general pattern.

Mounting evidence suggests multinational companies negligently sell products to the public that

are leading drivers of public health issues, while at the same time another division presents the

“remedy” to that same harm. A panacea for their own poison, as it were. In this way, they profit

twice: once when they supply the cause of our ailments, and again when we come to them for the cure.

It is clear that all is not well in Big Pharma these days. Americans have yet to coalesce around a

plan to impose transparency and integrity on health care and pharmaceutical companies.

Meanwhile, mounting evidence suggests the industry persists in the peddling hundreds of

products each year with dubious claims and even more dubious real-world effects — all while

maintaining stupefyingly high profit margins.

Sick and Getting Sicker

The real topics today are corporate consolidation and corruption. There may be no better

figurehead for this problem than everybody’s favorite “Family Company” (their words): Johnson

& Johnson. This is a family of more than 250 subsidiaries.

You will recall that the pharma giant’s talc-based baby powder is now inextricably linked to

incidences of ovarian cancer. Websites which concern themselves with preventing this type of

cancer specifically recommend omitting talcum powders from your daily constitutionals.

Fortunately enough for Johnson & Johnson’s bottom line, at least one company from their

panoply of subsidiaries — Janssen Pharmaceuticals — charitably offers chemotherapy drugs for

ovarian cancer patients for a mere $2,758 per dose. You can recognize it by the marketing-friendly name “Doxil.”

Let’s do another example.

You’re probably familiar with the sugar alternative called Equal. Equal and Canderel represent

the Merisant Corporation’s two most common and most profitable sugar substitutes currently on

the market. Mind you, such products are largely marketed toward health-conscious consumers

who wish to eliminate sugar from their diet.

The only trouble is, these products contain aspartame — and mounting evidence links

aspartame with Alzheimer’s disease, various cancers and multiple sclerosis.

Thankfully, MacAndrews & Forbes — the multinational that owns Merisant — also owns vTv

Therapeutics, which (you guessed it) makes a pretty penny selling treatments for literally every

health horror that aspartame allegedly contributes to.

Selling Snakeoil (With Government’s Help?)

report Advertisement

The False Claims Act exists for a reason in America, theoretically. Under its guidance,

corporations paid around $38.9 billion in damages and restitution between 1987 and 2013 for

lying to the public about what their products actually do.

But context is everything here. For scale, the United States’ entire GDP in 2016 was $18.5

trillion. What good is a $38-billion slap on the wrist, spread across 25 years and dozens of

corporations? And where’s the evidence that these weak, punitive, reactionary measures

actually get results? We need a system that prevents fraud — not one which reacts as an

afterthought after it’s already taken place.

The Politics of Corporate and Human Dignity

How do we fix this?

To begin with, we have to recognize that America is one of only two developed countries in the

world which allows pharmaceutical companies to market directly to consumers. They take

advantage of this by spending, collectively, $3 billion on advertising to convince Americans to

convince their doctors that they have a health concern worth writing a prescription for.

But what about the flagrant conflicts of interest like the ones we described above? How can it be

that corporations wield power equal to governments and owns both the means to make us sick and to cure us?

The answer is simple: America stopped enforcing antitrust laws some time ago.

Part of the reason why is because nearly everything about commerce is vastly different than it

was when anti-monopoly laws first hit our books. We didn’t envision a world where companies

could grow so diversified in the products they sell. We wrote our laws to tackle monopolies

within a single industry — we didn’t anticipate that a single company could dominate several

very different sectors. Look at what happened to the stocks of supermarket companies after

Amazon bought Whole Foods. That shouldn’t really be possible.

Then, overlay all of this with the cancerous influence of money in politics. Money has always

shaped policy, but it’s been getting worse and worse since the Supreme Court’s Citizens United

decision. Now, if policy is on the table — which might rein in corruption in a given industry —

hat industry mobilizes its army of lobbyists to kill that particular piece of legislation. Think of how

Big Telecom frequently buys off local politicians and then instructs them to put up roadblocks to

municipal broadband projects, which would easily deliver faster and cheaper service than

American ISPs are “legally” required to provide. And then they charge extra for higher speeds.

These are all symptoms of the same disease, and that disease is institutional greed. Greed is

why health care and many other products in America — even those which serve the public good

in an obvious way, such as health care, education and access to the internet — gets worse and

worse while simultaneously more expensive.

As the saying goes, “they’ve got us coming and going.”
Kate Harveston is an online journalist and the owner of political blog Only Slightly Biased. To follow her work, you can visit her blog or follow her on Twitter at @KateHarveston.
<< Previous
Bullboard Posts
Next >>